Trials / Withdrawn
WithdrawnNCT01762592
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Heidelberg Pharma AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study WX-20-002 will confirm diagnostic efficacy and safety of a PET/CT scan using Iodine (124I) Girentuximab performed during the diagnostic work-up in patients with indeterminate cT1-renal masses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iodine (124I) Girentuximab | i.v. |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2018-12-01
- Completion
- 2019-12-01
- First posted
- 2013-01-07
- Last updated
- 2017-12-22
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01762592. Inclusion in this directory is not an endorsement.